Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions

Biosimilar drugs, or highly similar copies of BA, will help reducing costs, but although EU has at least 40 biosimilars approved in 2018, the United States only has 5 commercially available.5 The most reported HSR were local reactions at the site of the injection (74%) followed by anaphylaxis (6.8%) and delayed exanthemas (5.1%). There is a lack of consensus of how to manage these HSR, which led us to suggest a decision tree flowchart (Figure E1, available in this article's Online Repository at www.jaci-inpractice.org), which should be validated in the near future.Acknowledgments The authors thank the French Allergy Syndicate for their help disseminating the survey to their members. All the authors critically revised and approved the final version of the manuscript and agree to be accountable for all the aspects of the work.Online Repository Survey Biological Treatments in Allergy: Prescription and Management of Hypersensitivity Reactions (English Version) ∗Mandatory Please indicate your age: ∗ Please indicate your gender: ∗ ○Male ○Female 3. The expenses of the treatments with biological agents prescribed for allergic and hypersensitivity conditions are:∗ Many possible responses. ○Completely covered by the national security ○Partially covered by the national security ○Completely covered by the private security ○Partially covered by the private security ○Part of research protocols or clinical trials ○Completely covered by the patient ○I don't know ○Other 12.